Phase I/II trial of IDEC-Y2B8 radioimmuno-therapy for treatment of relapsed or refractory CD20+ B-cell Non-Hodgkin’s Lymphoma - Witzig, TE; White, CA; Wiseman, GA (J Clin Oncol, 1999)